MetLife Investment Management’s Treace Medical Concepts TMCI Stock Holding History

MetLife Investment Management’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,540	Closed	-$185K	–	2873
2025 Q3	$185K	Hold	27,540	–	–	﹤0.01%	2364
2025 Q2	$162K	Hold	27,540	–	–	﹤0.01%	2294
2025 Q1	$231K	Sell	27,540 -506	-2%	-$4.55K	﹤0.01%	2122
2024 Q4	$209K	Hold	28,046	–	–	﹤0.01%	2287
2024 Q3	$163K	Hold	28,046	–	–	﹤0.01%	2391
2024 Q2	$187K	Buy	28,046 +3,978	+17%	+$32.1K	﹤0.01%	2295
2024 Q1	$314K	Hold	24,068	–	–	﹤0.01%	1934
2023 Q4	$307K	Hold	24,068	–	–	﹤0.01%	1979
2023 Q3	$316K	Hold	24,068	–	–	﹤0.01%	1910
2023 Q2	$616K	Buy	24,068 +5,031	+26%	+$130K	﹤0.01%	1562
2023 Q1	$480K	Hold	19,037	–	–	﹤0.01%	1676
2022 Q4	$438K	Hold	19,037	–	–	﹤0.01%	1726
2022 Q3	$420K	Hold	19,037	–	–	﹤0.01%	1757
2022 Q2	$273K	Hold	19,037	–	–	﹤0.01%	2088
2022 Q1	$360K	Buy	19,037 +6,788	+55%	+$132K	﹤0.01%	1984
2021 Q4	$228K	Buy	12,249 +7,004	+134%	+$145K	﹤0.01%	1975
2021 Q3	$141K	Hold	5,245	–	–	﹤0.01%	2281
2021 Q2	$164K	Buy	+5,245	New	+$167K	﹤0.01%	2274

Other funds holding TMCI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

MetLife Investment Management's TMCI Position: Q4 2025 in Review

MetLife Investment Management sold out of Treace Medical Concepts (TMCI) in Q4 2025, closing a stake of 27,540 shares — an estimated $185K sold.

MetLife Investment Management first reported a position in TMCI in Q2 2021 and held it in 18 quarters. The position peaked at $616K in Q2 2023. 115 funds tracked by Wall St. Rank hold TMCI as of Q4 2025.

MetLife Investment Management reported no remaining Treace Medical Concepts position as of Q4 2025 after selling out during the quarter.
MetLife Investment Management sold 27,540 Treace Medical Concepts shares in Q4 2025, an estimated $185K.
MetLife Investment Management first reported a position in Treace Medical Concepts in Q2 2021 and held it in 18 quarters.
MetLife Investment Management's Treace Medical Concepts position peaked at $616K in Q2 2023.
115 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2025.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.